European Organisation For Research & Treatment Of Cancer
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
- Conditions
- Advanced Hodgkin Lymphoma
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 150
- Registration Number
- NCT03517137
- Locations
- 🇧🇪
ZNA Stuivenberg, Antwerp, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇧🇪U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium
Follow-up in Gynecological Cancer Survivors
- Conditions
- Gynecologic Cancer
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 1100
- Registration Number
- NCT03515993
- Locations
- 🇦🇹
Medical University of Graz, Graz, Austria
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Other: Radiation TherapyDrug: Luteinising Hormone Releasing Hormone analog agonist (LHRHa)Drug: Non-steroidal anti-androgen
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
- Conditions
- Gastric and Esophagogastric Junction Adenocarcinoma
- Interventions
- Other: chemotherapy
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 197
- Registration Number
- NCT03443856
- Locations
- 🇨🇿
Masaryk Memorial Cancer Institute, Brno, Czechia
🇨🇿University Hospital Hradec Kralove, Hradec Králové, Czechia
🇫🇷CHRU de Lille - Hopital Huriez, Lille, France
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
- Conditions
- Inoperable œsophageal Cancer
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-02-21
- Target Recruit Count
- 8
- Registration Number
- NCT03437200
- Locations
- 🇫🇷
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere, Paris, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇪🇸Hospital Del Mar, Barcelona, Spain
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
- Conditions
- Mycosis Fungoides/Sezary SyndromeLymphoma, T-Cell, Cutaneous
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2024-02-22
- Target Recruit Count
- 26
- Registration Number
- NCT03357224
- Locations
- 🇪🇸
Hospital Universitario 12 De Octubre, Madrid, Spain
🇨🇭UniversitaetsSpital Zurich - Division of Dermatology, Zürich, Switzerland
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2025-07-01
- Target Recruit Count
- 749
- Registration Number
- NCT03345095
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸University of California at Irvine, Orange, California, United States
🇺🇸University of California, San Francisco, California, United States
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
- Conditions
- Squamous Non-small Cell Lung CancerNon-Squamous Non-small Cell Lung Cancer
- Interventions
Imaging Biomarker in Cancer Drug Induced ILD
- Conditions
- Drug Induced Interstitial Lung Disease (DIILD) Cancer Patients
- Interventions
- Other: Clinical evaluationsOther: Thoracic CT
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2017-09-29
- Target Recruit Count
- 70
- Registration Number
- NCT03294746
Pembrolizumab in Biliary Tract Cancer
- Conditions
- Biliary Tract CancerMetastatic CancerAdvanced CancerGallbladder Cancer
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2023-11-03
- Target Recruit Count
- 50
- Registration Number
- NCT03260712
- Locations
- 🇩🇪
Universitaetsklinikum Leipzig UCCL-Krebszentrum, Leipzig, Germany
🇩🇪Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz-University Medical Center, Mainz, Germany
🇪🇸Vall d'Hebron Institut Oncologia, Barcelona, Spain